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ABSTRACT 31 
Oral drug delivery systems for time-controlled release, intended for chronotherapy or colon 32 
targeting, are often in the form of coated dosage forms provided with swellable/soluble hydrophilic 33 
polymer coatings. The latter are responsible for programmable lag phases prior to release, due to 34 
their progressive hydration in the biological fluids. When based on high-viscosity polymers and/or 35 
manufactured by press-coating, the performance of functional hydroxypropyl methylcellulose 36 
(HPMC) layers was not fully satisfactory. Particularly, it encompassed an initial phase of slow 37 
release because of outward diffusion of the drug through a persistent gel barrier surrounding the 38 
core. To promote erosion of such a barrier, the use of a cellulolytic product (Sternzym C13030) 39 
was here explored. For this purpose, the dry mass loss behavior of tableted matrices based on 40 
various HPMC grades, containing increasing percentages of Sternzym® C13030, was preliminarily 41 
\studied, highlighting a clear and concentration-dependent effect of the enzyme especially with 42 
high-viscosity polymers. Subsequently, Sternzym C13030-containing systems, wherein the 43 
cellulolytic product was either incorporated into a high-viscosity HPMC coating or formed a 44 
separate underlying layer, were manufactured. Evaluated for release, such systems gave rise to more 45 
reproducible profiles, with shortened lag phases and reduced diffusional release, as compared to the 46 
reference formulation devoid of enzyme. 47 
 48 
 49 
   50 
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1. INTRODUCTION 51 
Several drug delivery systems for time-controlled release into the gastrointestinal tract, 52 
generally based on coated dosage forms or functional capsule shells, were proposed over the past 53 
three decades for chronopharmaceutical and colon targeting applications (Gazzaniga et al., 2011; 54 
Maroni et al., 2013, 2016; Melocchi et al., 2018). The relevant release-controlling layers were 55 
obtained using polymers having different physico-chemical properties, including swellable/soluble 56 
hydrophilic cellulose derivatives. By progressively interacting with the aqueous fluids, the latter 57 
polymers defer the onset of drug release until extensive dissolution/erosion of the gel barrier they 58 
form when undergoing glass-rubber transition.  59 
The application of the erodible functional layer of delivery systems for time-controlled release 60 
posed a novel challenge in the manufacturing of solid pharmaceuticals. The available techniques, 61 
i.e. double-compression (press-coating) and spray-coating, were both attempted. Press-coating 62 
offered advantages related to its solvent-free nature and, therefore, to the circumvented need for 63 
time- and energy-consuming drying steps (Foppoli et al., 2017). For these reasons, it also 64 
represented a technique with limited impact on the overall stability of the products. On the other 65 
hand, it required considerable amounts of powdered material to be applied, thus restraining the 66 
flexibility of the delivery technology. Moreover, depending on the physico-chemical and physico-67 
technological characteristics of the layer applied, it was demonstrated to yield excessively long-68 
lasting lag phases prior to release, which would be inconsistent with both the chronotherapeutic and 69 
colon delivery goals pursued. Importantly, relatively thick coatings having porous structure, as 70 
resulting from compaction processes, were also shown to give rise to initially slowed release due to 71 
outward diffusion of the drug through the hydrated polymer layer before its complete 72 
dissolution/erosion (Foppoli et al., 2019). This phenomenon would clearly clash with the prompt 73 
and quantitative release mode that would be desired at the end of the lag phase, being associated 74 
with diverse sigmoidal patterns. 75 
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Spray-coating was subsequently employed making use of hydro-organic film-forming 76 
systems. The resulting coated units showed satisfactory physico-technological characteristics and 77 
release performance. However, the use of organic solvents would no longer be of choice. Aqueous 78 
spray-coating, undertaken mainly in view of greater regulatory acceptability, involved longer 79 
processing time along with feasibility issues given the rheological characteristics of the film-80 
forming solutions. Despite all technical hurdles, aqueous-coated systems having the desired aspect 81 
and mechanical resistance were obtained following proper setup of the operating conditions. While 82 
the desired release patterns were attained with low-viscosity HPMC grades, the high-viscosity ones 83 
partly failed to meet expectations (Maroni et al., 2002). In this respect, Methocel K4M was shown 84 
to bring about a phase of diffusional release that was poorly evident in vitro though of major impact 85 
in vivo, thus impairing the overall performance of the delivery system that turned out more alike to 86 
a reservoir formulation for prolonged release (Figure 1). Furthermore, due to the marked release-87 
deferring ability of such polymers, possible difficulties were anticipated in fine modulation of the 88 
lag time through modification of the coating level.  89 
Therefore, release issues associated with coatings based on high-viscosity swellable/soluble 90 
polymers and/or manufactured by double-compression technique are still to be addressed. In order 91 
to overcome the aforementioned limitations, thereby broadening the scope of application of such a 92 
technique and of such polymers, formulation changes, to be introduced into the original design of 93 
the erodible systems, were needed. 94 
Based on these premises, the incorporation of cellulase, either in admixture with the 95 
functional coating polymer or separately loaded within a contiguous layer, was here explored with 96 
the aim of promoting erosion of the gel formed upon polymer hydration, thus preventing an 97 
enduring diffusional barrier from building up and affecting the rate of drug release over an extended 98 
time frame. Cellulases are enzymes or multienzymatic complexes produced by different 99 
microorganisms, which catalyze breakdown of cellulose and other structurally-related 100 
polysaccharides into glucose and cello-oligo saccharides (FAO, 1997). Such enzymes are widely 101 
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used in processing of food of plant origin, and in pulp and paper industry (Bhat, 2000; Bhat and 102 
Bhat, 1997; Jonas and Farah, 1998). They also have medical and biomedical applications, for the 103 
treatment of gastric phytobezoars and degradation of bacterial biofilms, and could be used as food 104 
supplements for fiber digestion and prebiotic purposes (Kramer and Pochapin, 2012) (Exercise.com. 105 
Cellulase, 2020). Exploitation of enzymes having cellulolytic activity has recently been proposed to 106 
turn pharmaceutical excipient microcrystalline cellulose into nanocellulose with improved tensile 107 
properties (Satyamurthy and Vigneshwaran, 2013). 108 
In the present work, the potential impact of a cellulolytic product of common use in the food 109 
industry (Sternzym® C13030) on the dissolution/erosion behavior of various HPMC grades was 110 
preliminarily studied by incorporating it into tableted polymer matrices, used as a model  111 
compression-coating, and performing dry mass loss experiments. Moreover, Sternzym C13030-112 
containing erodible systems for time-controlled release having diverse configuration were 113 
manufactured, using different coating techniques, and subsequently evaluated for release behavior. 114 
 115 
Figure 1:  saliva concentration profiles of acetaminophen after intake of uncoated cores and units 116 
coated with Methocel E5LV, E50LV and K4M up to 20% weight gain [adapted from 117 
Maroni et al., 2002]. 118 
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2. MATERIALS AND METHODS 123 
2.1 Materials 124 
Acetaminophen for direct compression (AMP, C.F.M., Italy), cellulose acetate propionate (CAP 125 
482-20, Eastman-Kodak, Tennessee), colloidal silica (Aerosil® 200, Evonik, Germany), 126 
ethylcellulose (Ethocel®, Dow Italia, Italy), hydroxypropyl methylcellulose 2910 USP (Methocel® 127 
E50LV, Mn=20000, Dow Italia) and 2208 USP (Methocel
® K100LV, Mn=26000; Methocel
® K4M, 128 
Mn=86000;  Methocel
® K15M, Mn=120000; Methocel
® K100M, Mn=220000), magnesium stearate 129 
(Carlo Erba Reagenti, Italy), maltodextrin (Glucidex® IT19W, Roquette, France), microcrystalline 130 
cellulose (Vivapur®101, JRS Pharma, Germany), sodium starch glycolate (Explotab®, JRS Pharma, 131 
Germany), Sternzym® C13030 (SternEnzym, Germany, a kind gift from IMCD Italia, Italy; 2500 132 
u/g enzymatic activity, expressed as hemicellulase according to DNS method at pH 6.0 as reported 133 
in the product technical data sheet). 134 
 135 
 136 
2.2     Methods 137 
Manufacturing of matrices 138 
Flat-faced cylindrical matrices (diameter 25 mm, nominal weight 1.0 g) were prepared by a rotary 139 
press (AM 8S, Officine Ronchi, Italy) from HPMC (Methocel® E50LV, Methocel®  K100LV, 140 
Methocel® K4M, Methocel® K15M and Methocel® K100M), either as such or in admixture with 141 
Sternzym® C13030 (1, 5 and 10%) or maltodextrin (10%), under approximately 2000 kg 142 
compaction force so that the resulting tablet had crushing strength in the range 70-100 N (crush 143 
tester TBH30 Erweka, Germany; n=10). The matrices were provided with an impermeable film, 144 
covering their whole surface except for one base, that was obtained by dipping into a 15% w/v CAP 145 
solution in acetone.  146 
 147 
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 148 
Mass loss experiments 149 
Partially coated units exposing a surface of constant area (n=3) were placed in the vessels of a 150 
paddle dissolution apparatus (Dissolution System 2000, Distek, New Jersey) containing 150 mL of 151 
deionized water thermostated at 37±1°C, so that the distance from the stirrer bottom and the matrix 152 
surface exposed to the fluid was 1.5 cm. The paddle rotation speed was set at 100 rpm. At fixed 153 
time points, 15 ml of fluid was withdrawn, replaced with fresh medium, and dried at 80°C to 154 
constant weight. Mass loss was assessed as the amount of solids recovered after drying of each fluid 155 
sample, and the relevant data were plotted against time to build cumulative curves. The rate of mass 156 
loss was calculated as the slope of the regression lines in the 1.5-6 h time frame.  157 
 158 
Manufacturing of tablet cores 159 
Acetominophen (80.0%), microcrystalline cellulose (14.5%), sodium starch glycolate (4.5%),  160 
magnesium stearate (0.5%) and colloidal silica (0.5%) were mixed in a V-blender (Erweka, 161 
Germany). The mixture was tableted by a rotary press equipped with concave punches (diameter 4 162 
mm, curvature radius 4 mm). The tablets were checked for weight (analytical balance BP211D 163 
Sartorius Mechatronics, Germany; n=20), height and diameter (digital micrometer Mitutoyo, Japan; 164 
n=20), crushing strength, friability (friabilometer TA3R Erweka, Germany) and disintegration time 165 
(three-position disintegration apparatus DT3 Sotax, Switzerland, n=6). The weight, height, 166 
diameter, crushing strength, friability and disintegration time were 39.0±0.5 mg, 3.092±0.028 mm, 167 
4.034±0.003 mm, 70±4N, < 1% and <5 min, respectively. 168 
 169 
Coating of tablet cores 170 
One-layer systems: Methocel® K4M, either as such or manually mixed with Sternzym® C13030 at 1 171 
and 5%, was applied onto tablet cores by manual press-coating using 80 mg of coating powder. Half 172 
of the powder was first introduced into the die (Ø 6 mm) of the tableting machine. The tablet core 173 
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was positioned centrally onto the pre-compressed powder bed. Then, the remainder of the coating 174 
powder was fed into the die and compaction forces of approximately 500 kg were applied, using 175 
concave punches with 6 mm curvature radius. 176 
Two-layer systems: an inner layer of Sternzym® C13030 and an outer layer of Methocel® K4M 177 
were applied by aqueous spray-coating in rotating pan (Ø 12 cm, GS, I) equipped with a two-way 178 
nozzle (mod 970/7-1 S75, Ø 1.2 mm, Düsen-Schlick, Untersiemau, Germany) and press-coating, 179 
respectively. Sternzym® C13030 amounted to 1% or 5% w/w of the applied amount of Methocel® 180 
K4M. In the two cases, coating solutions differing in composition were used for application of 181 
Sternzym® C13030 (Table I). Particularly, the addition of maltodextrin was aimed at having the 182 
same amount of solid material applied onto the cores by spray-coating, also enabling easier in-183 
process monitoring of the substrate growth. The cores were coated up to nominal weight gain of 184 
11%, under the following operating conditions: batch size 100 g; inlet air temperature 60 °C; 185 
product temperature 38 °C; pan rotation speed 30 rpm; nebulization air pressure 0.2 bar; solution 186 
spray rate 2.9 g/min . Methocel® K4M was then applied by press-coating, as described above. 187 
 188 
 189 
 190 
  191 
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Table I. Percentage composition of the coating solutions used for application of Sternzym® 192 
C13030 at 1% (A) or 5% (B) w/w of Methocel® K4M 193 
 A B 
Sternzym® C13030 2  10  
Maltodextrin 8 - 
PVP 1 1 
Distilled water 89 89 
 194 
 195 
 196 
 197 
 198 
 199 
Characterization of coated systems 200 
Coated systems were characterized for weight, height, diameter (n=20), crushing strength (n=10) 201 
and friability.  Coating thickness was calculated as half of the mean difference between the height 202 
and diameter of coated units and tablet cores, respectively. Photomicrographs of cross-sectioned 203 
systems were acquired by scanning electron microscope (SEM). Samples were gold-sputtered using 204 
a plasma evaporator under vacuum, and the photomicrographs were acquired at an accelerated 205 
voltage of 10 kV at 20 and 80x magnifications (Leo 1430, Carl Zeiss, Switzerland).  206 
For release studies, an adapted disintegration test method was used in order to avoid previously 207 
observed sticking of the swollen units to the vessels of the dissolution apparatus (Zema et al., 2007). 208 
Tests (n=3) were performed by Ph. Eur. 9.8 disintegration apparatus. Each unit was inserted into a 209 
basket-rack assembly so that only one of the 6 available tubes was occupied. The basket-rack 210 
assemblies moved in separate vessels at a constant 29 to 32 cycles/min frequency through a 55±2 211 
mm distance, immersed in 800 ml of distilled water at 37±1 °C. Fluid samples were withdrawn 212 
automatically at predetermined time points, and acetaminophen was quantified by 213 
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spectrophotometer at 248 nm (Lambda 25, Perkin Elmer, Italy). In the cumulative release profiles 214 
obtained, the duration of the lag phase prior to release (lag time) was assessed as the last time point 215 
before steep increase of the curve. 216 
 217 
 218 
 219 
 220 
3. RESULTS AND DISCUSSION  221 
3.1 Evaluation of mass loss from HPMC matrices containing cellulase 222 
The impact of cellulolytic enzymes on the performance of drug delivery systems based on 223 
hydrophilic cellulose derivatives has never been in-depth investigated, at least to the best of our 224 
knowledge. In order to preliminarily verify whether the enzyme may play any role in formulations 225 
for time-controlled release, the mass loss behavior of HPMC matrices was studied in the presence 226 
of cellulase. A commercially available enzymatic product (Sternzym® C13030), used in fruit and 227 
vegetable processing, was employed for this purpose. Sternzym® C13030 contains, in admixture 228 
with maltodextrin as a bulking agent, enzyme proteins with cellulolytic and various other hydrolytic 229 
activities, such as xylanase, glucanase and pectinase. Sternzym® C13030 appeared as a light brown 230 
powder formed from particles having d10 =45.52 μm, d50=99.88 μm and d90=203.01 μm size, as 231 
measured according to (Foglio et al., 2016). 232 
Different HPMC grades, covering a broad spectrum of applications in pharmaceutical 233 
formulation, were selected for the study: Methocel® E50LV, Methocel® K100LV, Methocel® K4M, 234 
Methocel® K15M and Methocel® K100M, having viscosity of 2% w/v aqueous solutions in the 50-235 
100000 cps range at 20°C. Cylindrical matrices based on each of these polymers, containing 236 
concentrations of Sternzym® C13030 of 1, 5 and 10%, were obtained by compaction and afterwards 237 
provided with an impermeable partial coating, so that a single surface of constant area could be 238 
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exposed to the medium. Partially coated matrices containing no cellulase, either composed of 239 
HPMC as such or in admixture with 10% of maltodextrin in the place of Sternzym® C13030, were 240 
also manufactured for comparison purposes. All matrices were tested in stirred thermostated water, 241 
and aliquots of fluid, withdrawn at programmed time points, were dried to constant weight in order 242 
to assess the amount of solids lost throughout the experiment. Particularly, the dry mass retrieved 243 
would result from i) dissolution of undegraded polymer, ii) enzymatic degradation of the polymeric 244 
chains and/or iii) mechanical erosion of swollen portions of the sample. 245 
The profiles of mass loss from matrices based on HPMC grades of increasing viscosity, with 246 
or without Sternzym® C13030, are reported in Figures 2-6. During the test, the free surface of the 247 
matrices showed smooth and homogeneous aspect, devoid of rough areas or evident dips, upon 248 
interaction with water. Moreover, no eroded fragments of the swollen polymer matrix were noticed 249 
in the medium.   250 
The process of mass loss in the time frame from 1.5 to 6 h was almost linear in all cases, 251 
although a tendency to initially slow mass loss could be observed, which was less pronounced with 252 
increasing enzyme percentages. Mass loss was found clearly affected by the enzyme, turning out to 253 
be enhanced in a concentration-dependent mode. Such an effect was generally highlighted even 254 
when the cellulolytic product was added at 1%, i.e. at the lowest percentage in the investigated 255 
range. Sternzym® C13030 was shown to impact on the mass loss behavior of matrices to a different 256 
extent depending on the HPMC grade. In particular, when the enzymatic product was added at 10% 257 
w/w, the rate of the process was almost doubled in the case of Methocel® E50LV and Methocel® 258 
K100LV, while an approximately ten-fold higher rate of mass loss was observed with Methocel® 259 
K4M, Methocel® K15M and Methocel® K100M. The greater differences observed in the case of the 260 
high-viscosity grades of HPMC could be ascribed to the inherently thicker and thus more persistent 261 
gel they form upon hydration, which would make enzymatic degradation of the polymer be 262 
reflected in a more evident tendency to dissolution and susceptibility to mechanical erosion. 263 
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 For comparison, the rates of mass loss obtained in the time frame from 1.5 to 6 h are 264 
comprehensively reported in Figure 7. From the histograms, the more marked stepwise increase in 265 
mass loss rate as a function of the concentration of Sternzym® C13030 shown by Methocel® K4M, 266 
Methocel® K15M and Methocel® K100M matrices is highlighted. In spite of the diverse molecular 267 
mass and viscosity, no major differences were observed among these polymers, which would be in 268 
line with comparable mass loss behavior of the relevant matrices devoid of enzyme under the 269 
investigated hydrodynamic conditions.  270 
Moreover, the low-viscosity polymers, namely Methocel® E50LV and Methocel® K100LV, 271 
considerably differed from each other in terms of extent to which the relevant mass loss behavior 272 
was influenced by the enzyme. Indeed, although the mass loss rate in the absence of Sternzym® 273 
C13030 was comparable, a much greater value was reached in the case of Methocel® K100LV 274 
when the enzymatic product was present at 10%. This gap might be due to the higher hydrophilicity 275 
of Methocel® K100LV vs Methocel® E50LV, in view of the lower degree of methoxyl substitution 276 
of series K polymers, and/or to its greater viscosity. 277 
 In order to verify whether highly water-soluble maltodextrin contained in Sternzym® 278 
C13030 may have played any role in bringing about the observed increase in mass loss rate, high-279 
viscosity HPMC-based matrices containing this excipient at 10% in the place of the enzymatic 280 
product were also evaluated (Figures 4-6). The influence of the sole maltodextrin turned out 281 
negligible. Indeed, the profiles of the maltodextrin-loaded matrices were almost superimposed on 282 
those relevant to the matrices based on HPMC as such. Therefore, it could be ruled out that simple 283 
osmotic and/or channeling effects, due to the soluble diluent contained in the enzymatic product, 284 
may be responsible for the enhanced rate of mass loss. Moreover, these results indicate that the 285 
cellulolytic activity of Sternzym® C13030 would not be impaired by compaction, at least at the 286 
forces employed for manufacturing of the matrices. 287 
  288 
14 
 
 289 
 290 
 291 
Figure 2:  profiles of mass loss vs time from Methocel® E50LV matrices containing differing 292 
amounts of cellulase (bars indicate SD). 293 
 294 
 295 
 296 
 297 
 298 
Figure 3:  profiles of mass loss vs time from Methocel® K100LV matrices containing differing 299 
amounts of cellulase (bars indicate SD). 300 
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 303 
Figure 4:  profiles of mass loss vs time from Methocel® K4M matrices containing differing amounts 304 
of cellulase (bars indicate SD). 305 
 306 
 307 
 308 
 309 
 310 
Figure 5: profiles of mass loss vs time from Methocel® K15M matrices containing differing 311 
amounts of cellulase (bars indicate SD). 312 
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 316 
 317 
Figure 6:  profiles of mass loss vs time from Methocel® K100M matrices containing differing 318 
amounts of cellulase (bars indicate SD). 319 
 320 
 321 
 322 
 323 
 324 
Figure 7: mass loss rate per unit area of matrices based on different HPMC grades as a function of 325 
Sternzym® C13030 concentration in the 1.5-6 h time frame (bars indicate 95% confidence 326 
interval). 327 
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3.2 Evaluation of systems coated with high-viscosity HPMC and cellulase 331 
 Once a clear effect of cellulase on mass loss from the polymeric matrices was demonstrated, 332 
especially evident with the higher viscosity HPMC grades, the outcome of incorporating Sternzym® 333 
C13030 into coated formulations for time-controlled release was evaluated. Among the high-334 
viscosity polymers investigated, which all showed comparable mass loss behavior, Methocel® K4M 335 
was selected for the study based on in vivo results previously obtained when it was applied as a 336 
functional coating layer. Indeed, such a polymer was demonstrated to impair the release 337 
performance of the coated dosage forms by generating an extended phase of slow release possibly 338 
due to diffusion of the drug through a persistent gel layer.  339 
In order to broadly explore the potential role of the enzyme, the cellulolytic product was 340 
incorporated, in nominal amounts of 1% and 5% with respect to the HPMC mass, into either the 341 
HPMC coating (one-layer configuration: 1LC-1St and 1LC-5St) or an underlying layer (two-layer 342 
configuration, 2LC-1St and 2LC-5St) of the delivery system (Table II). Press-coating was employed 343 
for application of Methocel® K4M, both as such and in admixture with Sternzym® C13030, onto 344 
immediate-release tablet cores. This technique was used in view of its well-known benefits as a 345 
simple dry-coating process coupled, however, with the critical impact of the rather elevated amount 346 
of coating powder needed, which would worsen the issues related to the use of a high-viscosity 347 
polymer. When the system was manufactured in its two-layer configuration, the application of 348 
Sternzym® C13030 as an aqueous solution was carried out by spray-coating. 349 
Coated units having uniform aspect and satisfactory physico-technological characteristics were 350 
obtained, irrespective of the configuration of the system (Figure 8). The compression-coatings 351 
exhibited even surface. While the inner Sternzym® C13030 film appeared continuous and uniform 352 
in thickness, the tableted layer, as expected, showed a more porous structure and higher variability 353 
in thickness. 354 
 355 
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Table II: outline of the systems under investigation and main physico-technological characteristics  356 
 Code
Nominal Sternzym 
concentration      
(% w/w on 
HPMC)
Weight           
(mg)
Coating              
(1 or 2 layers) 
thickness  
(µm)
Sternzym 
layer 
thickness*      
(µm)
u
n
co
at
ed
 
co
re
UC 39.0±0.5
o
n
e-
la
y
er
 
H
P
M
C
 c
o
at
ed
 
sy
st
em
1L.Me - 120.2±1.5 813±14
1L.Me1St 1 120.1±0.9 813±17
1L.Me5St 5 118.8±1.2 811±10
2L.Me1St 1 120.0±1.6 801±12 70±9
2L.Me5St 5 122.4±1.2 805±14 75±11
o
n
e-
la
y
er
 
H
P
M
C
/S
te
rn
zy
m
®
 
co
at
ed
 s
y
st
em
s
tw
o
-l
ay
er
 
H
P
M
C
/S
te
rn
zy
m
®
 
co
at
ed
 s
y
st
em
s
 357 
*thickness measured before application of the HPMC layer by press-coating 358 
 359 
 360 
 361 
 362 
 363 
 364 
 365 
 366 
 367 
 368 
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 369 
  370 
 371 
Figure 8:  picture of a core tablet, a coated system and one- and two-layer cross-sectioned systems 372 
(top image, left to right; graded notches in mm); SEM photomicrographs of a two-layer 373 
cross-sectioned system at 20x and 80x magnification (bottom images, left to right). 374 
 375 
 376 
 377 
 378 
The release performance of the systems manufactured in the one- and two-layer configurations 379 
was comparatively evaluated vs. the Methocel® 4KM-coated reference formulation (1LC.Me). In 380 
the absence of Sternzym® C13030, an average lag time of 540 min, i.e. the time to breakup of the 381 
system as indicated by steep increase in the release rate, was obtained (Figure 9). The profiles were 382 
characterized by marked variability and diffusional release covering most of the overall lag phase, 383 
up to approximately 20% of the drug content. This particular release pattern would be in agreement 384 
with the aforementioned pharmacokinetic results (Maroni et al., 2002). 385 
20 
 
The release curves from one-layer systems having Sternzym® C13030 within the HPMC coating 386 
(1LC.Me1St and 1LC.Me5St) were reproducible, and lag times turned out considerably reduced as 387 
a function of the amount of enzyme incorporated (Figure 10). The phase of slow outward diffusion 388 
of the drug through the swollen polymer layer appeared largely restrained both in terms of extent 389 
and duration. However, an earlier onset of this diffusion phenomenon was noticed with respect to 390 
the Methocel® K4M-coated units devoid of enzyme. Because the time to first detection of the drug 391 
in the test medium would result from the time the solvent takes to reach the core (swelling front 392 
movement) on the one hand, and the time the drug in solution takes to diffuse through the hydrated 393 
HPMC layer on the other, the presence of cellulase could have brought about faster water 394 
penetration due to polymer degradation and consequently decreased viscosity of the gel barrier. 395 
These concomitant phenomena would have also promoted erosion of the hydrated layer, thus 396 
leading to shorter diffusional path to be covered by the drug tracer. Such findings would be 397 
consistent with previously presented data of mass loss from matrices. 398 
 399 
  400 
Figure 9:  acetaminophen release profiles from uncoated cores and one-layer Methocel® K4M-401 
coated systems.  402 
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  404 
Figure 10:  acetaminophen release profiles from one-layer Methocel® K4M/Sternzym® C13030-405 
coated systems with increasing percentages of the enzymatic product. 406 
 407 
  408 
Figure 11:  acetaminophen release profiles from two-layer Methocel® K4M/Sternzym® C13030-409 
coated systems with increasing percentages of the enzymatic product. 410 
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In the profiles relevant to two-layer systems, having overlaid Sternzym® C13030 and 414 
Methocel® K4M layers (2LC.Me1St and 2LC.Me5St), the presence of the enzyme resulted in 415 
shortened lag phases, less evident diffusional release and reduced variability as compared with the 416 
system coated with HPMC only (1LC.Me) (Figure 11). Thus, the aqueous spray-coating process 417 
used to apply Sternzym® C13030 did not apparently hinder the effects of cellulase, at least to a 418 
major extent.  419 
The difference in lag time observed between the one-layer reference formulation (1LC.Me) 420 
and the Sternzym® C13030-containing two-layer systems (2LC.MeSt1 and 2LC.MeSt5) could only 421 
be ascribed to the phase of acetaminophen release, occurring by diffusion and unit breakup, rather 422 
than to that of aqueous medium penetration. Indeed, because of composition, thickness and 423 
manufacturing techniques of the HPMC coatings being equal, the time the solvent takes to reach the 424 
inner enzyme layer in the two-layer systems would be expected to approximately correspond to that 425 
it takes to reach the core in the one-layer reference formulation without enzyme.   426 
The impact of cellulase as incorporated in a separate layer (2L.MeSt1 and 2L.MeSt5), 427 
however, was lower with respect to when it was mixed with the swellable polymer (1L.MeSt1 and 428 
1L.MeSt5), and the influence of the enzyme concentration was also less pronounced.  429 
 430 
 431 
4. CONCLUSIONS 432 
Unsolved issues inherent in the performance of swellable/erodible coatings for time-controlled release, 433 
particularly manufactured by press-coating and/or from high-viscosity HPMC  needed to be addressed. With 434 
the aim of promoting faster and more consistent erosion of the diffusional barrier established upon polymer 435 
swelling, the incorporation of cellulolytic enzymes into either the coating or an underlying layer was here 436 
proposed. The viability of this approach was first assessed by studying the mass loss behavior of tableted 437 
matrices including increasing percentages of a commercially-available cellulolytic product in admixture with 438 
HPMC of viscosity grades spanning a wide range. Supported by the positive outcome of the preliminary 439 
23 
 
investigation, novel cellulase-containing systems were manufactured in the two differently devised 440 
configurations and evaluated. The release performance they provided was greatly improved as compared to 441 
the original formulation without enzymes. Indeed, previously observed issues of variable, excessively 442 
deferred in time and initially diffusional release were effectively prevented. Based on these overall results, 443 
the use of cellulase was shown to be a potentially advantageous strategy to obtain the desired pulsatile 444 
release behavior from time-controlled delivery systems having high-viscosity HPMC coatings, particularly 445 
when applied by press-coating. This would open up new perspectives in the application of such a technique, 446 
allowing functional cellulosic coatings to be manufactured with no need for using organic or aqueous 447 
solvents. Interestingly, the work performed not only would point out a potential role of cellulase as a release 448 
modulator but also suggest coupling diverse release-controlling polysaccharide agents with related hydrolytic 449 
enzymes might represent a novel approach in oral delivery and formulation, worthy of future investigation. 450 
 451 
 452 
 453 
  454 
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